斯瑞新材(688102.SH):擬使用約3.57億元募集資金向扶風銅合金增資 以實施募投項目
格隆匯3月23日丨斯瑞新材(688102.SH)公佈,陝西斯瑞扶風先進銅合金有限公司(“扶風銅合金”)系“年產4萬噸銅鐵和鉻鋯銅系列合金材料產業化項目(一期)”直接實施主體,為保障該募投項目順利實施,公司擬使用356,910,828.82元募集資金向全資子公司扶風銅合金增資用於實施上述募投項目,其中34000萬元計入註冊資本,剩餘1691.082882萬元計入資本公積,增資完成後,扶風銅合金註冊資本由6000萬元增加至40000萬元。扶風銅合金將根據募投項目的實施進度,分階段投入募投資金,以提高募集資金的使用效率,並定期按照募投項目實施進度,報吿募集資金使用情況。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.